Roche (ROG.VX) is buying U.S. diagnostics firm GeneWEAVE BioSciences for up to $425 million, expanding the Swiss group’s commitment to fighting so-called “superbugs” as the threat from drug-resistant microbes grows.
Roche said on Thursday it would pay shareholders in the privately held Californian company $190 million upfront and up to a further $235 million depending on the future success of its products.
{iframe}http://www.reuters.com/article/2015/08/13/us-roche-diagnostics-bacteria-idUSKCN0QI0OA20150813{/iframe}